Malaga Cove Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History

Malaga Cove Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 27, 2021	SELL	$26.72 - $33.19 $317,700 - $394,629	-11,890 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$24.15 - $31.45 $12,799 - $16,668	-530 Reduced 4.27%	11,890 $316,000
Q4 2020 Feb 05, 2021	SELL	$17.7 - $25.81 $16,514 - $24,080	-933 Reduced 6.99%	12,420 $310,000
Q2 2020 Jul 29, 2020	SELL	$17.09 - $24.89 $7,229 - $10,528	-423 Reduced 3.07%	13,353 $317,000
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $8,641 - $14,764	-598 Reduced 4.16%	13,776 $240,000
Q4 2019 Feb 13, 2020	SELL	$19.93 - $29.13 $3,786 - $5,534	-190 Reduced 1.3%	14,374 $341,000
Q3 2019 Oct 31, 2019	BUY	$25.47 - $33.37 $111,660 - $146,294	4,384 Added 43.06%	14,564 $400,000
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $9,707 - $12,593	-324 Reduced 3.08%	10,180 $337,000
Q4 2018 Feb 04, 2019	SELL	$30.84 - $49.51 $14,803 - $23,764	-480 Reduced 4.37%	10,504 $343,000
Q3 2018 Oct 15, 2018	BUY	$42.7 - $56.55 $469,016 - $621,145	10,984 New	10,984 $549,000

290

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.05B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Malaga Cove Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Malaga Cove Capital, LLC with notifications on news.